An elevated level of urinary 3-methoxytyramine (3MT) is tied to poor prognosis in pediatric neuroblastoma, according to research published in JCO Precision Oncology. Researchers also found that elevated 3MT was associated with 8 differentially expressed genes, providing a gene signature that correlated with an increase in MYC activity and poor survival outcomes.